Olpasiran
Highest phase reached
Phase 3
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Oligonucleotide
- Drug name
- Olpasiran
- all p ambo 5 o 25s 30s 39 2 acetamido 2 deoxy beta d galactopyranosyl oxy 25 30 bis 2 2 2 acetamido 2 deoxy beta d galactopyranosyl oxy ethoxy ethyl carbamoyl 1 23 28 33 tetraoxo 1 sulfanyl 2 5 8 11 14 17 20 37 octaoxa 24 29 34 triaza 1 lambda 5 phosphanonatriacontan 1 yl 2 o methyl p thiocytidylyl 3 5 2 o methyladenylyl 3 5 2 o methylguanylyl 3 5 2 o methylcytidylyl 3 5 2 o methylcytidylyl 3 5 2 o methylcytidylyl 3 5 2 o methylcytidylyl 3 5 2 o methyluridylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 o methyluridylyl 3 5 2 o methylguanylyl 3 5 2 o methyluridylyl 3 5 2 o methyluridylyl 3 5 2 o methyladenylyl 3 5 2 o methyluridylyl 3 5 2 o methyladenylyl 3 5 2 o methylcytidylyl 3 5 2 o methyl p thioguanylyl 3 3 2 deoxyadenosine duplex with all p ambo 2 o methyl p thioguanylyl 5 3 2 deoxy 2 fluoro p thiouridylyl 5 3 2 o methylcytidyly 5 3 2 deoxy 2 fluoroguanylyl 5 3 2 o methylguanylyl 5 3 2 deoxy 2 fluoroguanylyl 5 3 2 o methylguanylyl 5 3 2 deoxy 2 fluoroadenylyl 5 3 2 o methyladenylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 o methyladenylyl 5 3 2 o methyladenylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methyladenylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 o methyladenylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 o methyl p thioguanylyl 5 3 2 deoxy 2 fluoro p thiocytidylyl 5 3 2 o methyluridine
- ALL-P-AMBO-5'-O-((25S,30S)-39-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-25,30-BIS((2-(2-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)ETHOXY)ETHYL)CARBAMOYL)-1,23,28,33-TETRAOXO-1-SULFANYL-2,5,8,11,14,17,20,37-OCTAOXA-24,29,34-TRIAZA-1.LAMBDA.5-PHOSPHANONATRIACONTAN-1-YL)-2'-O-METHYL-P-THIOCYTIDYLYL-(3'->5')-2'-O-METHYLADENYLYL-(3'->5')-2'-O-METHYLGUANYLYL-(3'->5')-2'-O-METHYLCYTIDYLYL-(3'->5')-2'-O-METHYLCYTIDYLYL-(3'->5')-2'-O-METHYLCYTIDYLYL-(3'->5')-2'-O-METHYLCYTIDYLYL-(3'->5')-2'-O-METHYLURIDYLYL-(3'->5')-2'-DEOXY-2'-FLUOROURIDYLYL-(3'->5')-2'-DEOXY-2'-FLUOROADENYLYL-(3'->5')-2'-DEOXY-2'-FLUOROURIDYLYL-(3'->5')-2'-O-METHYLURIDYLYL-(3'->5')-2'-O-METHYLGUANYLYL-(3'->5')-2'-O-METHYLURIDYLYL-(3'->5')-2'-O-METHYLURIDYLYL-(3'->5')-2'-O-METHYLADENYLYL-(3'->5')-2'-O-METHYLURIDYLYL-(3'->5')-2'-O-METHYLADENYLYL-(3'->5')-2'-O-METHYLCYTIDYLYL-(3'->5')-2'-O-METHYL-P-THIOGUANYLYL-(3'->3')-2'-DEOXYADENOSINE DUPLEX WITH ALL-P-AMBO-2'-O-METHYL-P-THIOGUANYLYL-(5'->3')-2'-DEOXY-2'-FLUORO-P-THIOURIDYLYL-(5'->3')-2'-O-METHYLCYTIDYLY-(5'->3')-2'-DEOXY-2'-FLUOROGUANYLYL-(5'->3')-2'-O-METHYLGUANYLYL-(5'->3')-2'-DEOXY-2'-FLUOROGUANYLYL-(5'->3')-2'-O-METHYLGUANYLYL-(5'->3')-2'-DEOXY-2'-FLUOROADENYLYL-(5'->3')-2'-O-METHYLADENYLYL-(5'->3')-2'-DEOXY-2'-FLUOROURIDYLYL-(5'->3')-2'-O-METHYLADENYLYL-(5'->3')-2'-O-METHYLADENYLYL-(5'->3')-2'-O-METHYLCYTIDYLYL-(5'->3')-2'-O-METHYLADENYLYL-(5'->3')-2'-O-METHYLADENYLYL-(5'->3')-2'-DEOXY-2'-FLUOROURIDYLYL-(5'->3')-2'-O-METHYLADENYLYL-(5'->3')-2'-DEOXY-2'-FLUOROURIDYLYL-(5'->3')-2'-O-METHYL-P-THIOGUANYLYL-(5'->3')-2'-DEOXY-2'-FLUORO-P-THIOCYTIDYLYL-(5'->3')-2'-O-METHYLURIDINE
- amg 890
- Amg 890
- AMG 890
- AMG-890
- olpasiran
- Olpasiran
- olpasiran [INN]
- OLPASIRAN [USAN]
- Olpasiran [WHO-DD]
- olpasiran inn
- olpasiran usan
- olpasiran who dd
- rna cm sp am gm cm cm cm cm um 2 deoxy 2 fluoro u 2 deoxy 2 fluoro a 2 deoxy 2 fluoro u um gm um um am um am cm gm 3 3 sp da 5 o 23s 28s 37 2 acetylamino 2 deoxy beta d galactopyranosyl oxy 23 28 bis 2 2 2 acetylamino 2 deoxy beta d galactopyranosyl oxy ethoxy ethyl amino carbonyl 21 26 31 trioxo 3 6 9 12 15 18 35 heptaoxa 22 27 32 triazaheptatriacont 1 yl hydrogen phosphorothioate complex with rna um sp 2 deoxy 2 fluoro c sp gm 2 deoxy 2 fluoro u am 2 deoxy 2 fluoro u am am cm am am 2 deoxy 2 fluoro u am 2 deoxy 2 fluoro a gm 2 deoxy 2 fluoro g gm 2 deoxy 2 fluoro g cm sp 2 deoxy 2 fluoro u sp gm
- RNA, (CM-SP-AM-GM-CM-CM-CM-CM-UM-(2'-DEOXY-2'-FLUORO)U-(2'-DEOXY-2'-FLUORO)A-(2'-DEOXY-2'-FLUORO)U-UM-GM-UM-UM-AM-UM-AM-CM-GM-(3'->3')-SP-DA), 5'-(O-((23S,28S)-37-((2-(ACETYLAMINO)-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-23,28-BIS(((2-(2-((2-(ACETYLAMINO)-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)ETHOXY)ETHYL)AMINO)CARBONYL)-21,26,31-TRIOXO-3,6,9,12,15,18,35-HEPTAOXA-22,27,32-TRIAZAHEPTATRIACONT-1-YL) HYDROGEN PHOSPHOROTHIOATE), COMPLEX WITH RNA (UM-SP-(2'-DEOXY-2'-FLUORO)C-SP-GM-(2'-DEOXY-2'-FLUORO)U-AM-(2'-DEOXY-2'-FLUORO)U-AM-AM-CM-AM-AM-(2'-DEOXY-2'-FLUORO)U-AM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)G-GM-(2'-DEOXY-2'-FLUORO)G-CM-SP-(2'-DEOXY-2'-FLUORO)U-SP-GM)
- CAS registry numbers
- 2225856-03-9
- ChEMBL ID
- CHEMBL4650413
- FDA ingredient codes (UNII)
- 8M4GC1EOB4
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- olpasiran
- Type
- Nucleic acid
Mechanisms of action
- Mechanism
- LPA mRNA rnai inhibitor
- Action type
- RNAI_INHIBITOR
- Target
- LPA mRNA
- Protein identifier
- ENSG00000198670
Open Targets mechanisms
- Mechanism
- LPA mRNA rnai inhibitor
- Action type
- RNAI INHIBITOR
- Target
- LPA mRNA
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Atherosclerosis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003914
- Subject identifier
- D050197
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003914
- Condition identifier
- MONDO_0005311
- NCT03626662
- NCT04270760
- NCT05581303
- NCT05481411
- NCT05489614
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- R1=C-A-G-C-C-C-C-U-U-A-U-U-G-U-U-A-U-A-C-G=Ad G=U=C-G-G-G-G-A-A-U-A-A-C-A-A-U-A-U-G=C=U
Related records
Trials (10)
- A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)
- A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
- A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- Olpasiran Expanded Access Program
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
In development for (4)
- Atherosclerosis Phase 1
- Cardiovascular disorder Phase 3
- Kidney disorder Phase 1
- Liver disorder Phase 1
Targets (1)
- LPA LPA mRNA rnai inhibitor